Pancreatic cancer: Advances and challenges
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …
treatment of malignancies across a broad range of indications. Whereas initially, single …
Therapeutic targeting of tumour myeloid cells
ST Barry, DI Gabrilovich, OJ Sansom… - Nature Reviews …, 2023 - nature.com
Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …
Therapeutic developments in pancreatic cancer
ZI Hu, EM O'Reilly - Nature Reviews Gastroenterology & Hepatology, 2024 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …
lethal human malignancies. Much is known regarding the biology and pathophysiology of …
Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer
Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …
Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
We have shown that KRAS–TP53 genomic coalteration is associated with immune-excluded
microenvironments, chemoresistance, and poor survival in pancreatic ductal …
microenvironments, chemoresistance, and poor survival in pancreatic ductal …
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Inflammation and tissue damage associated with pancreatitis can precede or occur
concurrently with pancreatic ductal adenocarcinoma (PDAC). We demonstrate that in PDAC …
concurrently with pancreatic ductal adenocarcinoma (PDAC). We demonstrate that in PDAC …
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
Immunosuppression is a hallmark of pancreatic ductal adenocarcinoma (PDAC),
contributing to early metastasis and poor patient survival. Compared to the localized tumors …
contributing to early metastasis and poor patient survival. Compared to the localized tumors …
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
IK Kim, MS Diamond, S Yuan, SB Kemp… - Nature …, 2024 - nature.com
Acquired resistance to immunotherapy remains a critical yet incompletely understood
biological mechanism. Here, using a mouse model of pancreatic ductal adenocarcinoma …
biological mechanism. Here, using a mouse model of pancreatic ductal adenocarcinoma …
The role of immunotherapy in pancreatic cancer
R Mukherji, D Debnath, ML Hartley, MS Noel - Current Oncology, 2022 - mdpi.com
Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a
significant need for improved therapeutic options. While the recent breakthroughs of …
significant need for improved therapeutic options. While the recent breakthroughs of …